Ascentage Pharma Group International reported that on August 17, 2025, they received clearance from the US FDA and EMA for a global Phase III trial of Lisaftoclax for treating Myelodysplastic Syndrome. This filing is significant for the company as it indicates progress in their drug development efforts.